Acute myeloid leukemia (AML) is a form of blood cancer arising from abnormal white blood cell development in the bone marrow. AML is characterized by the presence of myeloblasts, also known as leukemic blasts, leading to an excessive production of immature white blood cells. This abnormal cell proliferation fills the bone marrow, hindering the production of healthy blood cells.
The primary treatment modalities for acute myeloid leukemia encompass chemotherapy, radiation therapy, stem cell transplant, and targeted therapy. Chemotherapy involves the use of potent drugs to eliminate rapidly dividing cells in the body. Various chemotherapeutic agents employed in the treatment of AML include cytarabine, anthracycline drugs, alkylating agents, anti-metabolites, tyrosine kinase inhibitors, and hormonal therapy. These drugs are administered in different regimens such as DC regimen, AVD regimen, and VCD regimen. Acute myeloid leukemia treatment is provided by various end-users, including hospitals, retail drug stores, ambulatory care centers, and clinics.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The acute myeloid leukemia market research report is one of a series of new reports from The Business Research Company that provides acute myeloid leukemia market statistics, including acute myeloid leukemia industry global market size, regional shares, competitors with an acute myeloid leukemia market share, detailed acute myeloid leukemia market segments, market trends and opportunities, and any further data you may need to thrive in the acute myeloid leukemia industry. This acute myeloid leukemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The acute myeloid leukemia market size has grown strongly in recent years. It will grow from $3.5 billion in 2024 to $3.73 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to growth aging population, environmental factors, genetic predisposition, limited treatment options, medical advancements.
The acute myeloid leukemia market size is expected to see strong growth in the next few years. It will grow to $4.9 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to growing advancements in targeted therapies, immunotherapies development, precision medicine approaches, increased awareness and early detection, collaborative research initiatives. Major trends in the forecast period include emphasis on minimal residual disease monitoring, integration of artificial intelligence (AI) in treatment decision support, focus on supportive care and quality of life interventions, collaborative research initiatives and clinical trials, patient advocacy and empowerment programs.
The forecast of 7.0% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The U.S. oncology sector could face significant challenges as tariffs increase costs for targeted therapy drugs and bone marrow transplant equipment imported from Switzerland and Japan, potentially delaying life-saving treatments for AML patients. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The anticipated growth in the acute myeloid leukemia market is driven by the expanding older population base and increasing unmet healthcare needs. This growth is particularly associated with the elderly population, aged 65 and above, facing health issues such as acute myeloid leukemia. In 2022, the American Cancer Society USA (ACS) reported that AML was prevalent among the elderly, with an average diagnosis age of 68 and notably low survival rates. AML affected around 60,650 individuals in 2022, resulting in 24,000 deaths. Hence, the geriatric population base and the rising healthcare needs contribute to the advancement of the acute myeloid leukemia market.
The growth of the acute myeloid leukemia market is further propelled by the increasing adoption of personalized medicine. This innovative medical approach takes into account individual variations in genes, environments, and lifestyles for treatment and healthcare. In the case of AML, personalized medicine involves molecular profiling to identify specific genetic mutations and biomarkers unique to each patient. This information guides the selection of targeted therapies and customized treatment plans, optimizing intervention effectiveness while minimizing adverse effects. In 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% classified as personalized medicines by the Personalized Medicine Coalition (PMC). Hence, the rising adoption of personalized medicine is a key driver for the growth of the acute myeloid leukemia market.
A notable trend in the acute myeloid leukemia market is the increasing focus on research and development (R&D) by pharmaceutical groups. R&D efforts aim to develop improved products and services to meet the demands of drug development. For example, a clinical trial titled 'Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs. Physician's Choice in Newly Diagnosed FLT3-ITD+ AML (Q-SOC)' is in Phase III, initiated in November 2021, and expected to conclude by March 2025, according to the National Library of Medicine.
Major companies in the acute myeloid leukemia market are concentrating on the development of advanced drug solutions, such as maintenance monotherapy, to enhance their product portfolios and address unmet medical needs. Maintenance monotherapy involves administering a single therapeutic agent as an ongoing, long-term therapy to prevent the recurrence or progression of a medical condition. In July 2023, Daiichi Sankyo Company Limited received approval from the United States Food and Drug Administration (USFDA) for quizartinib (Vanflyta) as maintenance monotherapy for newly diagnosed AML in adults with FLT3 internal tandem duplication (ITD)-positive status. The approval is based on positive results from the QuANTUM-First trial, demonstrating a significant improvement in overall survival. The dosage of quizartinib varies during induction, consolidation, and maintenance phases, and it is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation.
In March 2023, QIAGEN partnered with Servier Laboratories for an undisclosed amount to develop a companion diagnostic test for TIBSOVO, an isocitrate dehydrogenase-1 (IDH1) inhibitor intended for AML treatment. This collaboration aims to create and validate a real-time in vitro PCR test designed to detect IDH1 gene mutations in AML patients, using blood and bone marrow samples. The partnership enhances global accessibility to TIBSOVO for AML patients with IDH1 mutations and underscores QIAGEN's role in developing companion diagnostics for emerging biomarkers in onco-hematology, supporting precision medicine initiatives. Servier Laboratories, a France-based pharmaceutical company, is a key player in this collaboration.
Major companies operating in the acute myeloid leukemia market include Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Sanofi-Aventis (Genzyme Corporation), Bristol Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceuticals, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical, Celgene Corporation, Astellas Pharma, Servier Pharmaceuticals, CSPC Pharmaceutical Group, Genmab AS, Zhejiang Medicine Co. Ltd., Syndax Pharmaceuticals Inc., Astex Pharmaceuticals Inc., MEI Pharma Inc., SELLAS Life Sciences Group, Ambit Biosciences Corporation, Agios Pharmaceuticals Inc., Neomed Management AS, Oncolyze Inc., TC BioPharm, VERASTEM INC., Mirati Therapeutics Inc., Sunshine Lake Pharma, Sunesis Pharmaceuticals Inc.
North America was the largest region in the acute myeloid leukemia market in 2024. The regions covered in the acute myeloid leukemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the acute myeloid leukemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The acute myeloid leukemia market includes revenue earned by drugs such as DC regimen, AVD Regimen, VCD regimen, cytarabine, vidaza, dacogen, midostaurin, quizartinib, vosaroxin that are used for the treatment of acute myeloid leukemia. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Acute Myeloid Leukemia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on acute myeloid leukemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for acute myeloid leukemia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The acute myeloid leukemia market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Treatment Type: Chemotherapy; Radiation therapy; Stem Cell Transplant; Targeted Therapy
- 2) By Chemotherapy: Cytarabine; Anthracycline Drugs; Alkylating Agents; Anti-metabolites; Tyrosine Kinase Inhibitors; Hormonal Therapy
- 3) By Regimen: DC Regimen; AVD Regimen; VCD Regimen
- 4) By End-User: Hospital; Retails Drug Stores; Ambulatory Care Centers; Clinics
- Subsegments:
- 1) By Chemotherapy: Induction Chemotherapy; Consolidation Chemotherapy
- 2) By Radiation Therapy: Total Body Irradiation; Localized Radiation Therapy
- 3) By Stem Cell Transplant: Autologous Stem Cell Transplant; Allogeneic Stem Cell Transplant
- 4) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs); Monoclonal Antibodies; Other Targeted Agents
- Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; AbbVie Inc.; Novartis AG; Sanofi-Aventis (Genzyme Corporation); Bristol Myers Squibb Company; GlaxoSmithKline plc; Takeda Pharmaceuticals; Amgen Inc.; Otsuka Holdings Co. Ltd.; Teva Pharmaceutical; Celgene Corporation; Astellas Pharma; Servier Pharmaceuticals; CSPC Pharmaceutical Group; Genmab AS; Zhejiang Medicine Co. Ltd.; Syndax Pharmaceuticals Inc.; Astex Pharmaceuticals Inc.; MEI Pharma Inc.; SELLAS Life Sciences Group; Ambit Biosciences Corporation; Agios Pharmaceuticals Inc.; Neomed Management AS; Oncolyze Inc.; TC BioPharm; VERASTEM INC.; Mirati Therapeutics Inc.; Sunshine Lake Pharma; Sunesis Pharmaceuticals Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Acute Myeloid Leukemia Market Characteristics
3. Acute Myeloid Leukemia Market Trends And Strategies
4. Acute Myeloid Leukemia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Acute Myeloid Leukemia Growth Analysis And Strategic Analysis Framework
- 5.1. Global Acute Myeloid Leukemia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Acute Myeloid Leukemia Market Growth Rate Analysis
- 5.4. Global Acute Myeloid Leukemia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Acute Myeloid Leukemia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Acute Myeloid Leukemia Total Addressable Market (TAM)
6. Acute Myeloid Leukemia Market Segmentation
- 6.1. Global Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Chemotherapy
- Radiation therapy
- Stem Cell Transplant
- Targeted Therapy
- 6.2. Global Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Cytarabine
- Anthracycline Drugs
- Alkylating Agents
- Anti-metabolites
- Tyrosine Kinase Inhibitors
- Hormonal Therapy
- 6.3. Global Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- DC Regimen
- AVD Regimen
- VCD Regimen
- 6.4. Global Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital
- Retails Drug Stores
- Ambulatory Care Centers
- Clinics
- 6.5. Global Acute Myeloid Leukemia Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Induction Chemotherapy
- Consolidation Chemotherapy
- 6.6. Global Acute Myeloid Leukemia Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Total Body Irradiation
- Localized Radiation Therapy
- 6.7. Global Acute Myeloid Leukemia Market, Sub-Segmentation Of Stem Cell Transplant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Autologous Stem Cell Transplant
- Allogeneic Stem Cell Transplant
- 6.8. Global Acute Myeloid Leukemia Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Tyrosine Kinase Inhibitors (TKIs)
- Monoclonal Antibodies
- Other Targeted Agents
7. Acute Myeloid Leukemia Market Regional And Country Analysis
- 7.1. Global Acute Myeloid Leukemia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Acute Myeloid Leukemia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Acute Myeloid Leukemia Market
- 8.1. Asia-Pacific Acute Myeloid Leukemia Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Acute Myeloid Leukemia Market
- 9.1. China Acute Myeloid Leukemia Market Overview
- 9.2. China Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Acute Myeloid Leukemia Market
- 10.1. India Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Acute Myeloid Leukemia Market
- 11.1. Japan Acute Myeloid Leukemia Market Overview
- 11.2. Japan Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Acute Myeloid Leukemia Market
- 12.1. Australia Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Acute Myeloid Leukemia Market
- 13.1. Indonesia Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Acute Myeloid Leukemia Market
- 14.1. South Korea Acute Myeloid Leukemia Market Overview
- 14.2. South Korea Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Acute Myeloid Leukemia Market
- 15.1. Western Europe Acute Myeloid Leukemia Market Overview
- 15.2. Western Europe Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Acute Myeloid Leukemia Market
- 16.1. UK Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Acute Myeloid Leukemia Market
- 17.1. Germany Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Acute Myeloid Leukemia Market
- 18.1. France Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Acute Myeloid Leukemia Market
- 19.1. Italy Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Acute Myeloid Leukemia Market
- 20.1. Spain Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Acute Myeloid Leukemia Market
- 21.1. Eastern Europe Acute Myeloid Leukemia Market Overview
- 21.2. Eastern Europe Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Acute Myeloid Leukemia Market
- 22.1. Russia Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Acute Myeloid Leukemia Market
- 23.1. North America Acute Myeloid Leukemia Market Overview
- 23.2. North America Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Acute Myeloid Leukemia Market
- 24.1. USA Acute Myeloid Leukemia Market Overview
- 24.2. USA Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Acute Myeloid Leukemia Market
- 25.1. Canada Acute Myeloid Leukemia Market Overview
- 25.2. Canada Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Acute Myeloid Leukemia Market
- 26.1. South America Acute Myeloid Leukemia Market Overview
- 26.2. South America Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Acute Myeloid Leukemia Market
- 27.1. Brazil Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Acute Myeloid Leukemia Market
- 28.1. Middle East Acute Myeloid Leukemia Market Overview
- 28.2. Middle East Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Acute Myeloid Leukemia Market
- 29.1. Africa Acute Myeloid Leukemia Market Overview
- 29.2. Africa Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Acute Myeloid Leukemia Market Competitive Landscape And Company Profiles
- 30.1. Acute Myeloid Leukemia Market Competitive Landscape
- 30.2. Acute Myeloid Leukemia Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi-Aventis (Genzyme Corporation) Overview, Products and Services, Strategy and Financial Analysis
31. Acute Myeloid Leukemia Market Other Major And Innovative Companies
- 31.1. Bristol Myers Squibb Company
- 31.2. GlaxoSmithKline plc
- 31.3. Takeda Pharmaceuticals
- 31.4. Amgen Inc.
- 31.5. Otsuka Holdings Co. Ltd.
- 31.6. Teva Pharmaceutical
- 31.7. Celgene Corporation
- 31.8. Astellas Pharma
- 31.9. Servier Pharmaceuticals
- 31.10. CSPC Pharmaceutical Group
- 31.11. Genmab AS
- 31.12. Zhejiang Medicine Co. Ltd.
- 31.13. Syndax Pharmaceuticals Inc.
- 31.14. Astex Pharmaceuticals Inc.
- 31.15. MEI Pharma Inc.
32. Global Acute Myeloid Leukemia Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Acute Myeloid Leukemia Market
34. Recent Developments In The Acute Myeloid Leukemia Market
35. Acute Myeloid Leukemia Market High Potential Countries, Segments and Strategies
- 35.1 Acute Myeloid Leukemia Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Acute Myeloid Leukemia Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Acute Myeloid Leukemia Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
